Degradation study on sulfasalazine and a validated HPLC-UV method for its stability testing

Scientia Pharmaceutica

Volumn 82, Issue 2, 2014, Pages 295-306

  Saini, Balraj ^a   Bansal, Gulshan ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Forced degradation; HPLC; ICH; Stability indicating; Sulfasalazine

Indexed keywords

EID: 84903550041     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.1311-15     Document Type: Article

References (26)

1. Korolkovas A. Essentials of medicinal chemistry. 2008; Wiley, New York.
2. Moreland LW. Rheumatology & immunology therapy: A to Z essentials. 2004; Springer, New York. http://dx.doi.org/10.1007/3-540-29662-X
3. Davis Jr JC. Primer on the rheumatic diseases. Tthirteen ed. 2008; Springer, New York.
4. Bansal G, Singh R, Saini B, Bansal Y. ESI-MSn and LC-ESI-MS studies to characterize forced degradation products of bosentan and a validated stability-indicating LC-UV method. J Pharm Biomed Anal. 2013; 72: 186-197. http://dx.doi.org/10.1016/j.jpba.2012.08.014
5. Ollgaard H, Frost L, Galster J, Hansen OC. Survey of azo-colorants in Denmark: Consumption, use, health and environmental aspects. Copenhagen (DK): Ministry of Environment and Energy, Danish Environmental Protection Agency. 1998.
6. Weber EJ, Adams RL. Chemicals and sediment-mediated reduction of the azo dye Disperse Blue 79. Environ Sci Technol. 1995; 29: 1163-1170. http://dx.doi.org/10.1021/es00005a005
7. Albini A, Pietra S. Heterocyclic N-oxides. 1991; CRC Press. Inc., Florida.
8. Shu HY, Huang CR, Chang MC. Decolorization of monoazo dyes in wastewater by advanced oxidation process: A case study of acid red 1 and acid yellow 23. Chemosphere. 1994; 29: 2597-2607. http://dx.doi.org/10.1016/0045-6535(94)90060-4
9. British Pharmacopoeia. British Pharmacopoeia Commission, The Stationery Office, London, 2012, p. 2060.
10. ICH Q1A (R2), Stability testing of new drug substances and products, 2003.
11. ICH Q1B, Photostability testing on new drug substances and products, 1996.
12. Stone JC, Gorby R. Improved method for salicylazosulfapyridine analysis and partial characterization of impurities in commercial salicylazosulfapyridine. J Pharm Sci. 1974; 63: 1296-1298. http://dx.doi.org/10.1002/jps.2600630830
13. Bighley LD, McDonnell JP. High-speed liquid chromatographic analysis of sulfasalazine (salicylazosulfapyridine). J Pharm Sci. 1975; 6: 1549-1553. http://dx.doi.org/10.1002/jps.2600640930
14. Egli KL. Liquid chromatographic determination of sulfasalazine in tablets and bulk powder. J Assoc Off Anal Chem. 1985; 68: 803-806. http://www.ncbi.nlm.nih.gov/pubmed/2863249
15. Lanbeck K, Lindstrom B. Determination of salicylazosulphapyridine and sulphapyridine in plasma using high-performance liquid chromatography. J Chromatogr A. 1978; 154: 321-324. http://dx.doi.org/10.1016/S0021-9673(00)98488-7
16. Fischer C, Klotz U. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man. J Chromatogr A. 1979; 162: 237-243. http://dx.doi.org/10.1016/S0378-4347(00)81919-2
17. Shaw PN, Sivner AL, Aarons L, Houston JB. A rapid method for the simultaneous determination of the major metabolites of sulphasalazine in plasma. J Chromatogr. 1983; 274: 393-397. http://dx.doi.org/10.1016/S0378-4347(00)84450-3
18. Staniforth DH, Coates P, Clarke JG. An HPLC assay for sulphapyridine in plasma and its use to assess small bowel transit time after the administration of sulphasalazine. Int J Clin Pharmacol Ther Toxicol. 1987; 25: 406-409. http://www.ncbi.nlm.nih.gov/pubmed/2887521
19. Chungi VS, Rekhi GS, Shargel L. A simple and rapid liquid chromatographic method for the determination of major metabolites of sulfasalazine in biological fluids. J Pharm Sci. 1989; 78: 235-238. http://dx.doi.org/10.1002/jps.2600780313
20. Hansen SH. Simple and rapid method for the simultaneous determination of the eight main metabolites and conjugates of sulphasalazine in human plasma, urine and faeces using dynamically modified silica. J Chromatogr. 1989; 491: 175-178. http://dx.doi.org/10.1016/S0378-4347(00)82830-3
21. Buggé CJ, Gautam SR, Parke LE, Mason JT, Garcia DB. Simultaneous determination of sulfasalazine and its metabolites sulfapyridine and N-acetylsulfa-pyridine in human serum by ion-pair high-performance liquid chromatography using a polymer-based column. J Pharm Sci. 1990; 79: 1095-1098. http://dx.doi.org/10.1002/jps.2600791211
22. Peel N, Al-Dehaimi A, Colwell A, Russell G, Eastell R. Sulfasalazine may interfere with HPLC assay of urinary pyridinium crosslinks. Clin Chem. 1994; 40: 167-168. http://www.ncbi.nlm.nih.gov/pubmed/7904543
23. Coward S, Boa FG, Sherwood RA. Sulfasalazine interference with HPLC assay of 5-hydroxyindole-3-acetic acid. Clin Chem. 1995; 41: 765-766. http://www.ncbi.nlm.nih.gov/pubmed/7537188
24. Elmasry MS, Blagbrough IS, Rowan MG, Saleh HM, Kheir AA, Rogers PJ. Quantitative HPLC analysis of mebeverine, mesalazine, sulphasalazine and dispersible aspirin stored in a Venalink monitored dosage system with co-prescribed medicines. J Pharm Biomed Anal. 2011; 54: 646-652. http://dx.doi.org/10.1016/j.jpba.2010.10.002
25. Zalipsky JJ, Patel DM, Reavey-Cantwell NH. Characterization of impurities in sulfasalazine. J Pharm Sci. 1978; 67: 387-391. http://dx.doi.org/10.1002/jps.2600670331
26. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology, 2005.